Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications

From high dose semaglutide to cagrisema launch dates, Dave Knapp discusses how the latest Novo Nordisk earnings call impacts patients.

Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp
📱 Amazon Kindle Reader: https://amzn.to/4gAXrz4
📖Paperback: https://amzn.to/4gAXrz4

💊 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP
USE CODE "OTP10" to save 10%.

SOCIALS:
📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx
🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1
👾: https://discord.gg/ZHeUh7WV
📺: https://youtube.com/@ManOnTheMounjaro?feature=shared
❌: https://x.com/manonthepen?s=21
💻: https://www.onthepen.com